Search

Medetomidine

In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health. … Medetomidine is an intravenously available alpha-2 adrenergic agonist. The drug has been developed by Orion Pharma.

Distigmine

Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. … It improves detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity [A27176].

MLN3897

MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

R673

The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning

Ocaperidone

Tirapazamine

Tirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. … This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia.

Caldaret

Depatuxizumab mafodotin

Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.

Tegoprazan

Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fa...

R-851

R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and tumor cells.